Health and Fitness ARTICLE
Allergan wins FDA approval for Latisse
Published by Assam on December 27, 2008
Pharmaceutical firm Allergan Inc., the maker of Botox, said on Friday that the U.S. Food and Drug Administration (FDA) has approved its eyelash-thickening drug Latisse. The approval was based on the solution meeting the endpoints of improved eyelash prominence, length, thickness and darkness in a Phase 3, multi-center, double-masked and placebo controlled study.
Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, which means a person does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient that is in Allergan’s glaucoma treatment Lumigan. Patients taking Lumigan found a side effect of the drug to be eyelash growth, prompting Allergan to study it for the new use.
Allergan’s Latisse is a once a day prescription treatment that is applied to the base of the upper eyelash with a sterile, single-use, per eye disposable applicator. Once the Latisse treatment is stopped, eyelashes will gradually return to where they were prior to treatment.
Assam Information Portal
13 views
None
Watch Assamese Videos Online!